New data advance understanding of hypertensive disorders of pregnancy and confirm the economic value of targeted prevention strategies
Mirvie, a company dedicated to bringing a personalized, predictive, and preventive standard of care to pregnancy complications, today announced that two abstracts featuring data from its research programs will be presented as posters at the 2026 Society for Maternal-Fetal Medicine (SMFM) Annual Meeting.
Today, TIME revealed its annual list of the Best Inventions, which features extraordinary innovations changing our lives. Mirvie’s Encompass was named among the top Medical & Healthcare inventions of 2025.
Building on three decades of clinical leadership, WINMaternity’s expanded support—including 24/7 Nurse Advocacy, virtual specialists, biological data-driven screening, and engagement rewards—is designed to improve maternal health outcomes
WIN, the nation’s leading family-building and family wellness benefits provider, today announced the expansion of its maternal health solution, WINMaternity, backed by a partnership with Mirvie, a leader in delivering data-driven solutions for predictive and preventive care in pregnancy.
By relying on maternal characteristics and broad demographics, guidelines identify 9 out of 10 pregnancies at increased risk, resulting in ineffective preventive care
A new study sponsored by Mirvie, which is the first to evaluate U.S. Preventive Services Task Force (USPSTF) guidelines for preeclampsia risk and aspirin prescription in a single, nationally representative, prospective population, found while high-risk factors had sufficient value in estimating risk, there’s limited value for the moderate risk category - leading to nonspecific recommendations for aspirin use, a recognized prevention tool.
Starting with preeclampsia, new solution aims to transform the pregnancy experience from reactive to personalized, proactive and preventive by predicting risk for complications months before symptoms appear
Mirvie, a leader in uncovering the biology and utilizing data-driven approaches to improve the care of women’s health conditions, today announced the launch of its first breakthrough product for preeclampsia, one of the most common and serious pregnancy complications. Encompass™ combines a novel blood test to predict personalized preeclampsia risk with a preventive action plan and a responsive virtual assistant to offer pregnant women individualized support and help them work with their care team towards the healthiest pregnancy possible.
EncompassTM RNA test to help stratify asymptomatic pregnant women into high or low risk for preeclampsia, and support early preventive care interventions
Mirvie, Inc., in partnership with Advantia Health, has launched a first-of-its-kind pilot program in the U.S. to improve pregnancy outcomes. The program uses the clinically validated Encompass Preeclampsia Test (powered by the Mirvie RNA Platform) to assess high and low risk for preeclampsia, enabling clinicians to initiate preventive care for the appropriate patients.
Landmark research published in Nature Communications advances the biological understanding of hypertensive disorders of pregnancy, unlocking the potential for personalized care
Mirvie announced results of a breakthrough study published in Nature Communications, revealing new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia - a leading cause of maternal morbidity and mortality as well as preterm birth.
Research presented at the Society for Maternal-Fetal Medicine annual meeting demonstrates Mirvie’s breakthrough technology can predict babies with severe growth restriction, a leading cause of stillbirth
Mirvie, a pioneer in bringing a personalized, predictive, and preventive approach to serious pregnancy complications, today announced at the Society for Maternal-Fetal Medicine annual meeting that the Mirvie RNA platform has uncovered a unique molecular signature predictive for babies born with severe growth restriction. Unrecognized fetal growth restriction is the single largest risk factor for stillbirth.
The new findings build upon previous research demonstrating the utility of the Mirvie RNA platform to predict pregnancy complications months before symptoms appear
Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy.
Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced Aimee Corso joins the company as Senior Vice President of Growth. Recognized for advancing patient engagement and empowerment in healthcare by creating a more patient-centric view of healthcare delivery, she will lead the launch of Mirvie’s first test using RNA to predict pregnancy complications months in advance.
